Management guidelines and outcome measures in giant cell arteritis (PMR)

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Giant cell arteritis (GCA) is a common form of vasculitis that predominantly affects the elderly. Cranial symptoms and elevated inflammatory markers are suggestive of the condition and the diagnosis is usually established by temporal artery biopsy. Corticosteroids are the mainstay of treatment for GCA and prolonged therapy is often necessary. Disease relapses and steroid-related adverse effects, however, are common. Serious complications of the disease may include visual loss, stroke, and aortic involvement with aneurysm formation.

Original languageEnglish (US)
JournalClinical and Experimental Rheumatology
Volume25
Issue number6 SUPPL. 47
StatePublished - 2007

Fingerprint

Giant Cell Arteritis
Outcome Assessment (Health Care)
Guidelines
Temporal Arteries
Vasculitis
Aneurysm
Adrenal Cortex Hormones
Stroke
Steroids
Biopsy
Recurrence
Therapeutics

Keywords

  • Aneursym
  • Corticosteroids
  • Giant cell arteritis
  • Polymyalgia rheumatica headache
  • Vasculitis

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

@article{8c45dd60a2ef49de867a47c76bdaa8c1,
title = "Management guidelines and outcome measures in giant cell arteritis (PMR)",
abstract = "Giant cell arteritis (GCA) is a common form of vasculitis that predominantly affects the elderly. Cranial symptoms and elevated inflammatory markers are suggestive of the condition and the diagnosis is usually established by temporal artery biopsy. Corticosteroids are the mainstay of treatment for GCA and prolonged therapy is often necessary. Disease relapses and steroid-related adverse effects, however, are common. Serious complications of the disease may include visual loss, stroke, and aortic involvement with aneurysm formation.",
keywords = "Aneursym, Corticosteroids, Giant cell arteritis, Polymyalgia rheumatica headache, Vasculitis",
author = "Warrington, {Kenneth J} and Matteson, {Eric Lawrence}",
year = "2007",
language = "English (US)",
volume = "25",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "6 SUPPL. 47",

}

TY - JOUR

T1 - Management guidelines and outcome measures in giant cell arteritis (PMR)

AU - Warrington, Kenneth J

AU - Matteson, Eric Lawrence

PY - 2007

Y1 - 2007

N2 - Giant cell arteritis (GCA) is a common form of vasculitis that predominantly affects the elderly. Cranial symptoms and elevated inflammatory markers are suggestive of the condition and the diagnosis is usually established by temporal artery biopsy. Corticosteroids are the mainstay of treatment for GCA and prolonged therapy is often necessary. Disease relapses and steroid-related adverse effects, however, are common. Serious complications of the disease may include visual loss, stroke, and aortic involvement with aneurysm formation.

AB - Giant cell arteritis (GCA) is a common form of vasculitis that predominantly affects the elderly. Cranial symptoms and elevated inflammatory markers are suggestive of the condition and the diagnosis is usually established by temporal artery biopsy. Corticosteroids are the mainstay of treatment for GCA and prolonged therapy is often necessary. Disease relapses and steroid-related adverse effects, however, are common. Serious complications of the disease may include visual loss, stroke, and aortic involvement with aneurysm formation.

KW - Aneursym

KW - Corticosteroids

KW - Giant cell arteritis

KW - Polymyalgia rheumatica headache

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=36448929143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448929143&partnerID=8YFLogxK

M3 - Article

C2 - 18021519

AN - SCOPUS:36448929143

VL - 25

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 6 SUPPL. 47

ER -